Skip to main content
Browse by:
GROUP

Until further notice, in-person public events have been canceled. This includes recruitment events, tours, student programs, reunions, performances, conferences and social events.
Event listings include how to access online content. Contact event sponsor with questions.
Please note that all visitors to campus must comply with Duke’s community safety measures, which include wearing a mask,
check https://returnto.duke.edu/campus-visitors/ before coming to campus, and follow direction provided by campus personnel.

Opportunities in Alzheimer's Disease Prevention: TOMMORROW - A Clinical Trial to Delay the Onset of Mild Cognitive Impairment

Kathleen Welsh-Bohmer, PhD, ABPP-cn
Icon calendar
Thursday, February 27, 2020
Icon time
12:00 pm - 1:00 pm
Icon speaker
Kathleen Welsh-Bohmer, PhD, ABPP-cn
Icon series
Psychiatry and Behavioral Sciences Grand Rounds

Sponsored by the Hans Lowenbach Memorial Fund. Dr. Kathleen Welsh-Bohmer is a Professor of Psychiatry and Neurology at Duke University. Clinically trained as a neuropsychologist, her research activities have been focused around developing effective prevention and treatment strategies to delay the onset of cognitive disorders occurring in later life. She was the Principal Investigator of the Cache County Memory Study (2002-2013), an epidemiological study of an exceptionally long- lived population that established key environmental modifiers affecting Alzheimer's disease onset and progression. Since 2006 she has directed the Joseph and Kathleen Bryan Alzheimer's Center at Duke University, where she has led a large multidisciplinary team focused around the genetic determinants of Alzheimer's disease and speeding drug discoveries to prevent and treat neurodegenerative diseases. She has served as the neuropsychology lead for the TOMMORROW program, a global clinical trial to delay the onset of mild cognitive impairment due to Alzheimer's disease. very recently, she was appointed to the Duke Clinical Research Institute (DCRI), an academic clinical research organization, to oversee its interventional trials within the Alzheimer's disease therapeutic area. Concurrently, she is leading science strategy for neurodegenerative disorders.

Contact: Angela Garrett